VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesMarketEarningsCompareWatchlistInsider
CTSOCytosorbents Corporation
$0.41$26M
Research
Overview
Valuation
ValuationTargetsPrice
Financials
RevenueEarningsP/ERatiosDividend
Ownership
Holders
Tools
Total ReturnDCA Calculator
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

Follow VCP Scanner on XFollow VCP Scanner on LinkedIn
© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksCTSOEarnings History

CTSO logoCytosorbents Corporation (CTSO) Earnings History

Net Loss

21 years of earnings data (2005–2025) · Currently unprofitable on a TTM basis

TTM Net Income
-$12M
● Net Loss
TTM EPS (Diluted)
$-0.19
Per share, diluted
YoY EPS Growth
+65.8%
Excellent
Net Margin
-22.1%
After-tax profitability
EPS Growth Rate (CAGR)
1YN/A
3YN/A
5YN/A
10YN/A
Operating Margin-38.4%
Gross Margin71.5%
Return on Equity-96.4%
Return on Assets-17.9%
Record Annual Net Income-$80,000FY2005
Record Quarterly EPS$0.05Q2 2015
Consecutive Profitable Years0years
Q1 2026
Net Income-$5M
EPS (Diluted)$-0.08
YoY Growth+65.8%Excellent
QoQ Growth+6.7%Solid

Loading earnings history...

Cytosorbents Corporation (CTSO) Earnings Overview

As of June 23, 2026, Cytosorbents Corporation (CTSO) reported trailing twelve-month net income of -$12M, reflecting +65.8% year-over-year growth. The company earned $-0.19 per diluted share over the past four quarters, with a net profit margin of -22.1%.

Looking at the long-term picture, CTSO's historical earnings data spans multiple years. The company achieved its highest annual net income of -$80,000 in fiscal 2005.

Cytosorbents Corporation is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →

Compared to peers including NVCR (-$173M net income, -20.8% margin), MASI ($76M net income, -9.9% margin), ICUI ($46M net income, 0.0% margin), CTSO has room to improve margins relative to the peer group. Compare CTSO vs NVCR →

CTSO Earnings vs Peers

Earnings metrics vs comparable public companies

CompanyTTM Net IncomeTTM EPSNet MarginROEYoY GrowthCompare
CTSO logoCTSOCurrent
-$12M$-0.19-22.1%-96.4%+65.8%—
NVCR logoNVCR
-$173M$-1.52-20.8%-38.9%+21.8%
MASI logoMASI
$76M$1.45-9.9%-17.1%+51.0%
ICUI logoICUI
$46M$1.840.0%0.0%+100.6%
LMAT logoLMAT
$62M$2.7123.1%15.8%+30.6%
ATRC logoATRC
-$5M$-0.09-2.1%-2.4%+74.7%
Best in group
Lowest in group

CTSO Historical Earnings Data (2005–2025)

21 years
Fiscal Year Net Income YoY % Operating Income EPS (Diluted) Net Margin Op. Margin
2025-$8M+60.4%-$14M$-0.13-22.1%-38.4%
2024-$21M+29.2%-$16M$-0.38-58.2%-46.2%
2023-$29M+10.9%-$32M$-0.65-94.1%-102.8%
2022-$33M-33.6%-$32M$-0.75-94.6%-90.9%
2021-$25M-213.4%-$23M$-0.57-61.2%-56.7%
2020-$8M+59.3%-$10M$-0.20-19.9%-26.3%
2019-$19M-11.9%-$19M$-0.60-84.6%-83.3%
2018-$17M-103.4%-$16M$-0.56-85.0%-77.0%
2017-$8M+29.1%-$10M$-0.31-63.2%-73.6%
2016-$12M-46.8%-$11M$-0.47-145.5%-140.0%
2015-$8M+12.8%-$9M$-0.33-200.5%-229.4%
2014-$9M-99.3%-$7M$-0.65-296.4%-231.4%
2013-$5M-27.7%-$5M$-0.50-569.2%-573.5%
2012-$4M+33.2%-$3M$-0.46-2417.0%-2303.1%
2011-$5M-88.4%-$4M$-0.86-15193.9%-12297.7%
2010-$3M-6.3%-$3M$-0.74--
2009-$3M+9.3%-$2M$-1.64--
2008-$3M+9.9%-$3M$-3.00--
2007-$3M+56.3%-$3M$-3.37--
2006-$8M-9489.5%-$3M$-7.87--
2005$-80,000-$-80,000$-0.26-800.0%-800.0%

Download Data

Export CTSO earnings history in CSV or JSON format

Free sign-in required to download data

Consensus-Based Analysis Tools

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

21+ years return with dividends reinvested.

Calculate

DCA Calculator

See how regular investing compounds over time.

Run Numbers

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

CTSO — Frequently Asked Questions

Quick answers to the most common questions about buying CTSO stock.

What is CTSO earnings per share (EPS)?

CTSO trailing twelve-month (TTM) diluted EPS is $-0.19, reflecting +65.8% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2005 to 2025 is available in the table on this page.

What is Cytosorbents Corporation's net income?

Cytosorbents Corporation (CTSO) trailing twelve-month net income is $-12M as of 2025. Earnings grew +65.8% year-over-year.

Is CTSO profitable?

CTSO is not currently profitable on a TTM basis, reporting a net loss of $-12M. Net margin is -22.1%. Investors should monitor for a return to profitability.

What is CTSO's earnings growth rate?

CTSO compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2005 to 2025.

What are CTSO's profit margins?

Cytosorbents Corporation net profit margin is -22.1%, operating margin is -38.4%, and gross margin is +71.5%. Below-average margins reflect competitive or cost pressures. Return on Equity is -96.4%.

Is CTSO growing earnings?

Yes, CTSO earnings are accelerating — EPS growth of +65.8% exceeds the 5-year CAGR of N/A. TTM net income reached $-12M. Earnings momentum is strengthening.

What was CTSO's best earnings year?

Cytosorbents Corporation's highest annual net income on record is $-80000.00, achieved in fiscal year 2005. Earnings history on this page spans 2005 to 2025 and includes all annual and quarterly figures.

What were CTSO's earnings last quarter?

CTSO's most recent reported quarter was Q1 2026. Net income was $-5M with diluted EPS of $-0.08. For a full breakdown of all quarters, see the quarterly earnings table on this page.

CTSO Earnings Over Time (2005–2025)

Net income & EPS — annual and quarterly view